唑来膦酸联合放射性核素^(89)Sr治疗晚期前列腺癌骨转移疼痛  

Immediate effects of Zoledronic acid combined Strontium-89 palliative therapy in prostate cancer patients with bone metastases

作　　者：沈伟华[1] 徐庆康[1] 于永涛[1] 李伟飞[1] 陈峰[1] 于田强[1] 徐哲丰[1] 

机构地区：[1]武警浙江总队医院泌尿外科,嘉兴314000

出　　处：《中国男科学杂志》2008年第1期28-30,共3页Chinese Journal of Andrology

摘　　要：目的探讨晚期前列腺癌骨转移性疼痛的理想治疗方法。方法23例确诊为前列腺癌且有多处骨转移病灶伴有疼痛患者,经静脉滴注唑来膦酸同时,辅以核素89Sr静脉内注射内放疗及部分病灶外放射治疗。结果疼痛缓解率3个月为82.6%,6个月为91.3%,9个月为86.9%。骨转移病灶数量明显减少,肿瘤标志物PSA较前明显下降。结论该方案治疗前列腺癌骨转移性疼痛安全、有效,可以提高患者生活质量。Objective To evaluate the effects of Zoledronic acid combined Strontium-89 palliative therapy in prostate cancer patients with bone metastases. Methods 23patients of prostate cancer with bone metastases received Zoledronic acid with strontium-89 chloride（^89Sr）, and part of them received radiotherapy. Results The pain was relieved. Relief occurred in 82.6% of the patients for 3 months, 91.3% for 6months and 86.9% for 9 months. The number of bone metastases and serum PSA was reduced. Conclusion Zoledronic acid with ^89Sr is effective palliative and more safe treatment for pain from bone metastases in patient with prostate cancer.

关 键 词：前列腺肿瘤 骨转移性疼痛 唑来膦酸 ^89锶 放射疗法 

分 类 号：R737.25[医药卫生—肿瘤]